Docosahexaenoic Acid, Fish Oil and Omega-3 Fatty Acids: study protocols
4 study groups took Docosahexaenoic Acid together with Fish Oil and Omega-3 Fatty Acids. These are the doses the studies gave. They are not a recommendation.
Fewer than 5 study groups in one unit match, too few to draw the chart.
Commonly used together
1 of 4 study groups took Docosahexaenoic Acid, Fish Oil and Omega-3 Fatty Acids with something else, but nothing that 3 or more different studies gave.
4 study groups
| Study | |||||
|---|---|---|---|---|---|
| Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease 2017 · Lovaza · Adults aged 36–80 with stable coronary artery disease and overweight/obesity or metabolic-syndrome features; included participants with and without type 2 diabetes | 1.5 g | 3.36 g | 1.86 g | 1 year | 147 |
| Synbiotic Bacillus megaterium DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study 2024 · Fish oil group · Healthy men and women aged 30–75 years, selected as at-risk individuals with omega-3 index ≤6.5% and elevated AGEs and/or hsCRP | 120 mg | 180 mg | 180 mg | 4 weeks | — |
| Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study 2019 · PUFA supplementation alone · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed | 800 mg | 800 mg | 225 mg | 3 years | 401 |
| Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study 2019 · PUFA supplementation + multidomain intervention · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed | 800 mg | 800 mg | 225 mg | 3 years | 399 |